The SIRT1-activating compounds upregulate SIRT1 expression to reduce cisplatin- or hemorrhagic-shock-induced AKI, directly impacting catalase expression, eliminating free radicals, and promoting ATP generation [82,84,104]. The gene discussed is SIRT1; the disease is Shock.